01 Increasing Adoption of Non-Invasive and At-Home Screening Methods Stool-based tests can be completed at home, while newer blood-based technologies provide another non-invasive option for eligible average-risk adults. This transition is broadening the range of screening modalities available to patients and increasing the importance of convenience and accessibility in screening programs. In June 2026, the CDC stated that several colorectal cancer screening tests can be performed at home and continued to recommend screening for adults aged 45 to 75, reinforcing the role of non-invasive approaches in routine screening.
02 Emergence of Blood-Based Molecular Screening Technologies The market is increasingly incorporating blood-based molecular technologies that analyze circulating tumor-derived DNA and related biological signals. These tests are designed to provide a less invasive screening option for average-risk populations and can potentially address barriers associated with stool collection and endoscopic procedures. Regulatory acceptance of blood-based screening is therefore expanding the technological landscape of colorectal cancer detection. In July 2024, the FDA approved Shield as a blood-based colorectal cancer screening test for average-risk adults aged 45 years and older, marking a major regulatory development for molecular blood-based screening.
01 Lower Screening Age Recommendations Expand the Eligible Population The lowering of the recommended starting age for average-risk colorectal cancer screening expands the population eligible for routine screening and creates additional demand for screening tests, laboratory services, imaging, and follow-up procedures. In June 2026, the CDC continued to recommend colorectal cancer screening beginning at age 45 for most adults, with screening generally recommended through age 75.
01 Need for Colonoscopy After Abnormal Non-Invasive Results Limits Standalone Screening Convenience Non-invasive screening methods do not eliminate the need for diagnostic colonoscopy when results are abnormal. Patients receiving positive stool, blood-based, or other non-invasive screening results generally require colonoscopy to determine the presence and extent of disease and, where appropriate, remove lesions. This additional procedure can increase healthcare utilization and may reduce the perceived convenience advantage of non-invasive screening.
01 Expansion of Blood-Based Screening Creates Opportunities for Molecular Diagnostic Providers Blood-based screening creates opportunities for diagnostic companies developing molecular assays that can detect colorectal cancer-associated biological changes from blood samples. Providers that can demonstrate reliable detection while meeting regulatory and clinical requirements can address the large population that remains insufficiently screened.
01 Persistent Screening Gaps and Unequal Participation Challenge Market Expansion The effectiveness of colorectal cancer screening programs depends not only on the availability of tests but also on participation, timely completion, and follow-up after abnormal results. Differences in healthcare access, awareness, socioeconomic conditions, and willingness to undergo screening can leave substantial portions of the eligible population unscreened. Screening providers therefore face the challenge of improving participation while ensuring that abnormal results lead to appropriate diagnostic evaluation.
March 2026 Exact Sciences expanded its colorectal cancer screening portfolio with advancements in non-invasive diagnostic testing solutions designed to improve early detection and screening accessibility.
September 2025 Guardant Health advanced its blood-based cancer screening technologies through clinical development initiatives focused on improving early cancer detection, including colorectal cancer applications.
May 2025 F. Hoffmann-La Roche expanded its diagnostics portfolio with new molecular testing and screening solutions to support early cancer detection and personalized healthcare approaches.